Immunotherapeutic approaches in the treatment of COVID-19



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The novel coronavirus SARS-CoV-2 has caused a life-threatening disease COVID-19 provoked a pandemic over the world. The effectual host immune response including innate and adaptive immunity against SARS-Cov-2 seems crucial to control and resolve the viral infection. However, the severity and outcome of the COVID-19 might be associated with the excessive production of pro-inflammatory cytokines "cytokine storm” leading to an acute respiratory distress syndrome. Regretfully, the exact immunophysiology and treatment, especially for the severe COVID-19, is still uncertain. Novel therapeutic strategies are urgently needed to eliminate the viral reservoir in the host. In this review, we described several potential strategies for immunotherapy to cure SARS-CoV-2 infection. This may provide clue of using immune therapy as combine treatment to prevent the patient develop into severe respiratory syndrome and largely reduced complications.

Full Text

Restricted Access

About the authors

E. V Abakushina

A.F. Tsyb Medical Radiological Research Center - branch of the National Medical Research Radiological Center of the Ministry of Health of the Russian Federation

Email: abakushina@mail.ru

References

  1. Zhou P., Yang X.L., Wang X.G. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798): 270-3.
  2. Lazear H.M., Schoggins J.W., Diamond M.S. Shared and distinct functions of type I and type III interferons. Immunity 2019; 50(4): 907-23.
  3. Ben Addi A., Lefort A., Hua X. et al. Modulation of murine dendritic cell function by adenine nucleotides and adenosine: involvement of the A (2B) receptor. Eur. J. Immunol. 2008; 38(6): 1610-20.
  4. de Wit E., van Doremalen N., Falzarano D., Munster V.J. SARS and MERS: recent insights into emerging cronaviruses. Nat. Rev. Microbiol. 2016; 14(8): 523-34.
  5. Alunno A., Padjen I., Fanouriakis A., Boumpas D.T. Pathogenic and therapeutic relevance of JAK/STAT signaling in systemic lupus erythematosus: integration of distinct inflammatory pathways and the prospect of their inhibition with an oral agent. Cells 2019; 8(8): 898. doi: 10.3390/cells8080898.
  6. Kindler E., Thiel V., Weber F. Interaction of SARS and MERS coronaviruses with the antiviral interferon response. Adv. Virus Res. 2016; 96: 219-43.
  7. Lu X., Pan J., Tao J., Guo D. SARS-CoV nucleocapsid protein antagonizes IFN-beta response by targeting initial step of IFN-beta induction pathway, and its C-terminal region is critical for the antagonism. Virus Genes. 2011; 42(1): 37-45.
  8. Cron R.Q., Chatham W.W. The rheumatologist’s role in Covid-19. J. Rheumatol. 2020; 47(5): 639-42.
  9. Tisoncik J.R., Korth M.J., Simmons C.P., et al. Into the eye of the cytokine storm. Microbiol. Mol. Biol. Rev. 2012; 76: 16-32.
  10. Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 2017; 39: 529-39.
  11. Qin C., Zhou L., Hu Z. et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin. Infect. Dis. 2020; 71(15): 762-8.
  12. Chen G., Wu D., Guo W. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 2020; 130(5): 2620-9.
  13. National Health Commission of the People's Republic of China The Diagnosis and Treatment Plan for 2019-nCoV (accessed 4 March 2020). The Seventh Trial Edition www.nhc.gov.cn/yzygj/s7653p/202003/46c9 294a7dfe4cef80dc7f5912eb1989.shtml.
  14. Guan W-j., Ni Z-y., Hu Y. et al. Clinical characteristics of coronavirus Disease 2019 in China. N. Engl. J. Med. 2020 382: 1708-20.
  15. Wan S., Yi Q., Fan S. et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv 2020.02.10.20021832. doi: https://doi.org/10.1101/2020.02.10.20021832.
  16. Xu Z., Shi L., Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020; 8: 420-2.
  17. Chousterman B.G., Swirski F.K., Weber G.F. Cytokine storm and sepsis disease pathogenesis. Semin. Immunopathol. 2017; 39: 517-28.
  18. Chiappelli F., Khakshooy A., Greenberg G. CoViD-19 Immunopathology and Immunotherapy. Bioinformation 2020; 16(3): 219-22.
  19. Chen N., Zhou M., Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507-13.
  20. Wang D., Hu B., Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061-9.
  21. Yao X.H., Li T.Y., He Z.C. et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. Chin. J. Pathol. 2020; 49(5): 411-7.
  22. Shimabukuro-Vornhagen A., Godel P., Subklewe M. et al. Cytokine release syndrome. J. Immunother. Cancer 2018; 6: 56.
  23. Временные методические рекомендации: профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Утверж. Е.Г. Камкин. Версия 8, 03.09.2020.
  24. Деев Р.В. Клеточная трансплантация в программе лечения COVID-19: пересадка стволовых стромальных (мезенхимальных) клеток. Гены и Клетки 2020; 15(2): 9-17.
  25. Behrens E.M., Koretzky G.A. Review: cytokine storm syndrome: looking toward the precision medicine era. Arthritis Rheumatol. 2017; 69: 1135-43.
  26. Ferro F., Elefante E., Baldini C., et al. COVID-19: the new challenge for rheumatologists. Clin. Exp. Rheumatol. 2020; 38(2): 175-80.
  27. D'Antiga L. Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transpl. 2020; 26(6): 832-4.
  28. Samuel C.E. Antiviral actions of interferons. Clin. Microbiol. Rev. 2001; 14: 778-809.
  29. Shen K.L., Yang Y.H. Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue. World J. Pediatr. 2020: 6-8.
  30. Lokugamage K.G., Schindewolf C., Menachery V.D. SARS-CoV-2 sensitive to type I. interferon pretreatment. Bio Rxiv. 2020.
  31. Sheahan T.P., Sims A.C., Leist S.R. et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. 2020; 11: 222. https://doi. org/10.1038/s41467-019-13940-6.
  32. Menachery V.D., Yount B.L., Josset L. et al. Attenuation and restoration of severe acute respiratory syndrome coronavirus mutant lacking 2’-O-methyltransferase activity. J. Virol. 2014; 88: 4251-64.
  33. Stockman L.J., Bellamy R., Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006; 3: 1525-31.
  34. Dong L., Hu S., Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov. Ther. 2020; 14: 58-60.
  35. Bellingan G., Maksimow M., Howell D.C. et al. The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. Lancet Respir. Med. 2014; 2: 98-107.
  36. Ranieri V.M., Pettila V., Karvonen M.K. et al. Effect of intravenous interferon p-1a on death and days free from mechanical ventilation among patients with moderate to severe acute respiratory distress syndrome: a randomized clinical trial. JAMA 2020; 323: 725-33.
  37. Sallard E., Lescure F.X., Yazdanpanah Y. et al. Type 1 interferons as a potential treatment against COVID-19. Antiviral. Res. 2020; 178: 104791.
  38. Mair-Jenkins J., Saavedra-Campos M., Baillie J. K. et al. The effectiveness of convalescent plasma and hyper immune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J. Infect. Dis. 201 5; 211(1): 80-90.
  39. Casadevall A., Pirofski L.A. The convalescent sera option for containing COVID-19. J. Clin. Invest. 2020; 130(4): 1545-8.
  40. Michot J.M., Albiges L., Chaput N. et al. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann. Oncol. 2020; 31(7): 961-4.
  41. Zhang X., Song K., Tong F., et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv. 2020; 4(7): 1307-10.
  42. Genentech Announces FDA approval of clinical trial for Actemra to treat hospitalized patients with severe COVID-19 pneumonia, https:// www.gene.com/media/press-releases/14843/2020-03-23/ genentech-announces-fda-approval-of-clin.
  43. Sanofi and Regeneron begin global Kevzara® (sarilumab) clinical trial program in patients with severe COVID-19, http://www.news.sanofi. us/2020-03-16-Sanofi-and-Regeneron-begin-global-Kevzara-R-sarilumab-clinical-trial-program-in-patients-with-severe-COVID-19.
  44. Ascierto P.A., Fox B.A., Urba W.J. et al. Insights from immuno-oncology: the society for immunotherapy of cancer statement on access to IL-6-targeting therapies for COVID-19. J. Imm. Ther. Cancer 2020; 8: e000878.
  45. Henter J.I., Chow C.B., Leung C.W. et al. Cytotoxic therapy for severe avian influenza A (H5N1) infection. Lancet 2006; 367(9513): 870-3.
  46. Sonmez H.E., Demir S., Bilginer Y., Ozen S. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clin. Rheumatol. 2018; 37(12): 3329-35.
  47. Maschalidi S., Sepulveda F.E., Garrigue A. et al. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. Blood 2016; 128(1): 60-71.
  48. Cron R.Q., Chatham W.W. The rheumatologist’s role in COVID-19. J. Rheumatol. 2020; 47(5): 639-42.
  49. Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395 (10229): 1054-62.
  50. Uccelli A., de Rosbo N.K. The immunomodulatory function of mesenchymal stem cells: mode of action and pathways. Ann. N.Y. Acad. Sci., 2015; 1351: 114-26.
  51. Ben-Mordechai T., Palevski D., Glucksam-Galnoy Y. et al. Targeting macrophage subsets for infarct repair. J. Cardiovasc. Pharmacol. Ther. 2015; 20(1): 36-51.
  52. Lee J.W., Fang X.H., Krasnodembskaya A. et al. Concise review: Mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem cells 2011; 29(6): 913-9.
  53. Jinxin Q., Chengchao D., Xian J., Yong G. Advances in developing CAR T-cell therapy for HIV cure Front. Immunol. 2020; 11: 361.
  54. Adipose-derived mesenchymal stem cells in acute respiratory Distress Syndrome COVID-19, SARS-CoV-2. NCT04280224.
  55. Adipose-derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome COVID-19. NCT04324996.
  56. Adipose-derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome COVID-19, SARS-CoV-2. NCT04344548.
  57. Zhang C., Liu J., Zhong J.F., Zhang X. Engineering CAR-T cells. Biomark. Res. 2017; 5: 22.
  58. Ramos C.A., Dotti G. Chimericantigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert. Opin. Biol. Ther. 2011; 11: 855-73.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies